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The herpes simplex virus type 1 tegument protein VP22 is known to be highly phosphorylated during infection. Here we
show that two electrophoretic forms of VP22 can be identified in infected cell extracts and that this heterogeneity is
accounted for by phosphorylation. Furthermore, the nonphosphorylated form of VP22 appears to be specifically incorporated
into virions. We also show that the phosphorylated form of VP22 is the only form detected during transient transfection
and as such that VP22 can act as a substrate for a cellular kinase. Phospho-amino acid and phospho-peptide analyses of
in vivo labeled VP22 were utilized to demonstrate that the phosphorylation profiles of VP22 synthesized during transfection
and infection are the same. In both cases VP22 was modified solely on serine residues located in the N-terminal 120
residues of the protein. Moreover, in vitro phosphorylation was utilized to show that the constitutive cellular kinase, casein
kinase II, which has four serine consensus recognition sites at the N-terminus of VP22, phosphorylates VP22 in the same
manner as observed in vivo. This kinase also phosphorylates VP22 at the N-terminus in intact capsid–tegument structures.
Casein kinase II is therefore likely to be the major kinase of VP22 during infection. q 1996 Academic Press, Inc.
The herpes simplex virus type 1 (HSV-1) structural pro- recognition sites for cellular kinases (see Fig. 2), and
thus VP22 may act as a substrate for a viral kinase, atein VP22 is a major component of the virus tegument
(1), the region situated between the capsid and the enve- cellular kinase, or both. In this report we describe the
mapping of the region of VP22 which is phosphorylatedlope of the virion. However, the role of VP22 in the infec-
tious cycle is unclear. Several studies have suggested in vivo, during both infection and transient transfection. In
both situations the phosphorylation profile was identical,that VP22 can interact with HSV-1 DNA (2–4) and that it
may associate with the nuclear matrix at some time dur- occurring only at the N-terminus of the protein, and spe-
cifically on serine residues. In vitro kinase assays wereing infection (4), but the relevance of these results is yet
to be determined. In our attempts to define the role of utilized to implicate the cellular kinase, casein kinase II
(CKII), in the modification of VP22. In addition, in theVP22, we have recently shown that it interacts specifi-
cally with the acidic activation domain of VP16 (5), a context of intact capsid-tegument structures VP22 was
tegument protein which functions as the transactivator one of only two virion proteins which acted as an efficient
of IE gene expression (6 –8). These results indicate that substrate for CKII in vitro. Moreover, we demonstrate that
VP22 may be involved in several aspects of virus replica- VP22 present within the virion is a nonphosphorylated
tion including regulation of VP16 activity and virion as- form of that found in the cell, suggesting that assembling
sembly. particles specifically incorporate this form of the protein.
VP22 is a 38K basic protein encoded by the UL49 gene VP22 from different sources was initially characterized
(9), which is located among the cluster of genes UL46 – by Western blotting. Total cell extracts were made from
UL49, all of which encode tegument components (10– COS-1 cells either infected with HSV-1 strain 17 (m.o.i.
12). VP22 appears to be posttranslationally modified in of 10) and harvested 20 hr postinfection or transfected
several ways. In particular, VP22 is heavily phosphory- with the VP22 expression vector pGE109 (9) and har-
lated in infected cell extracts (2, 9), but the kinase respon- vested 40 hr posttransfection. In addition, a total extract
sible for phosphorylation of VP22 is unknown. Recent in of purified extracellular virions (strain 17), purified from
vitro studies have implicated the putative viral kinase, infected BHK-21 cells on a 5–15% Ficoll gradient as de-
the product of UL13, in this role (13). However, the VP22 scribed previously (14), was analyzed. The samples were
open reading frame contains 16% serines and threo- electrophoresed on a 10% polyacrylamide gel, which was
nines, many of which are contained within consensus transferred to nitrocellulose, and reacted with the poly-
clonal anti-VP22 antibody AGV30, raised against a GST-
VP22 fusion protein. Interestingly, VP22 synthesized dur-1 To whom correspondence and reprint requests should be ad-
dressed. Fax: 01883 714375. E-mail: G.Elliott@MCRI.ac.uk. ing transient transfection migrated with a slower mobility
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FIG. 1. (a) VP22 exists in two forms. Equivalent amounts of total HSV-1 infected COS-1 cell extract, and pGE109 transfected COS-1 cell extract
were electrophoresed on a 10% polyacrylamide gel and analyzed by Western blotting, together with a sample of purified extracellular HSV-1 virions.
The blot was reacted with the polyclonal anti-VP22 antibody, AGV 30. The two species of VP22 are indicated by arrows. (b) VP22 is phosphorylated
in both transfected and infected cell extracts. In vivo 32P-labeled extracts of mock, pGE109 transfected, and HSV-1 infected cells were immunoprecipi-
tated with antibody AGV 30 and analyzed by SDS–PAGE on a 12% polyacrylamide gel. Total samples (Total) and immunoprecipitated samples (IP)
are shown. M, mock; T, pGE109 transfected; I, HSV-1 infected, COS-1 cells. (c) The upper form of VP22 is phosphorylated. HSV-1 infected COS-1
cell extract was incubated for 30 min at 377 in either the absence (0) or the presence (/) of alkaline phosphatase and analyzed by Western blotting.
The two forms of VP22 are indicated by arrows.
than that present in the intact virion (Fig. 1a, compare beads were then added and incubated for 1 hr at 47, and
the immunoprecipitated samples were washed five timeslanes T and V). Moreover, VP22 synthesized in the in-
fected cell appeared as a broad band on the blot (Fig. in 50 mM Tris–HCl (pH 7.5), 150 mM NaCl, and 0.1%
NP-40. Both total and immunoprecipitated samples were1a, lane I), ranging in migration from that seen in the
virion (222) to that present during transfection (221). analyzed by SDS–PAGE. VP22 immunoprecipitated from
infected cell extract was phosphorylated (Fig. 1b, IP sam-The presence of VP22 species with varying mobility
in our infected cell extract suggested that differentially ples, compare lanes M and I). Moreover, analysis of the
total phosphorylated profile of infected cells revealed thatmodified forms of the protein are synthesized during in-
fection. VP22 has previously been shown to be phosphor- VP22 represents one of the major infected cell phospho-
proteins (Fig. 1b, total samples, lane I). In addition, immu-ylated in infected cells, a modification which could ac-
count for the shift in mobility. By contrast, the phosphory- noprecipitation of the transfected cell extract clearly
demonstrated that VP22 is phosphorylated during trans-lation status of VP22 synthesized during transfection, and
thus in the absence of other viral gene products, has not fection (Fig. 1b, IP samples, lane T). These results sug-
gest that 221 represents a phosphorylated form of VP22yet been reported, but the presence of only one species
in such an extract, that is 221, allowed us to determine and therefore that VP22 can act as a substrate for a
cellular kinase.the level of phosphorylation on this form of VP22. COS-
1 cells, which had been either mock transfected, trans- The sample of VP22 which was immunoprecipitated
from infected cells appeared to contain only one 32P-fected with plasmid pGE109 24 hr previously, or infected
with HSV-1 strain 17 (m.o.i. of 10) 4 hr previously, were labeled band in its profile (Fig. 1b, IP samples, lane I),
suggesting that 222 observed in Western blotting (Fig.incubated in the presence of [32P]orthophosphate (50
mCi/ml) for 16 hr, harvested in PBS, and soluble proteins 1a, lane I) may represent the unmodified form of VP22.
To determine if 222 is a nonphosphorylated form of 221extracted by freeze–thawing in a buffer containing 10
mM HEPES (pH 7.9), 400 mM NaCl, 0.1 mM EDTA, and a sample of infected cell extract, solubilized in the buffer
described above, was treated with 5 units of calf intesti-0.5 mM DTT. An equal volume of a buffer containing 10
mM HEPES (pH 7.9), 0.1 mM EDTA, and 0.5 mM DTT was nal alkaline phosphatase (AP) in 50 mM Tris (pH 8.5), 0.1
mM EDTA for 30 min at 377, electrophoresed on a 10%added to the extracts to give a final NaCl concentration of
200 mM, and immunoprecipitations of VP22 were carried gel, and analyzed by Western blotting. Treatment with AP
caused an obvious change in mobility of the predominantout. Antibody AGV30 was added to the extracts, which
were incubated for 2 hr at 47. Protein A–Sepharose species of VP22 in the infected cell extract from 221 in
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FIG. 2. Line drawing of the VP22 open reading frame (ORF). The endolysine cleavage map is shown beneath the ORF, along with the predicted
Mr of the individual peptides. The relative positions of the consensus PKC and CKII phosphorylation sites are shown above the line. S, serine; T,
threonine. Note that there are no consensus PKA sites. At the top of the figure are shown the open reading frames for the C-terminal deletion
mutants of VP22. l, epitope tag.
untreated extract (Fig. 1c, lane 0) to 222 in AP treated (Boehringer-Mannheim), as described previously (16).
The resulting peptides were analysed by high-resolutionextract (Fig. 1c, lane /). Taken together these results
demonstrate that VP22 exists in two major forms within urea/SDS–PAGE (17). Cleavage of both infected-cell and
transfected-cell VP22 resulted in the presence of onlythe cell—the faster migrating form (222), which is the
species present in the virus particle and which is also one 32P-labeled peptide with a Mr of around 20K (Fig.
3c). Analysis of the endo-lysine cleavage map of VP22detectable in the infected cell, and the slower migrating
form (221), which represents the phosphorylated version (Fig. 2) reveals that there is only one large peptide in the
open reading frame which covers the N-terminus of theof 222 and which is present in both transfected and in-
fected cells. protein and has an apparent Mr of 13K. While the peptide
we observed migrated more slowly than this, it is likelyWhile VP22 is phosphorylated in both the absence and
the presence of other viral products, it is possible that that the high level of VP22 phosphorylation would cause
it to migrate aberrantly. It is noteworthy that while full-different phosphorylation sites and/or different kinases
are utilized in either situation. The open reading frame length VP22 migrates at 38K, its predicted molecular
weight is only 32.2K (see also below).for VP22 is extremely Ser/Thr rich, and there are multiple
consensus recognition sites for the cellular kinases CKII The endolysine mapping of VP22 predicts that the ma-
jority of phosphorylation occurs within the N-terminal 140and protein kinase C (PKC), but none for protein kinase
A (Fig. 2). To initially characterize VP22 phosphorylation, residues. Thus, to confirm phosphorylation at the N-ter-
minus, we analyzed three variants of VP22, kindly pro-we determined the relative phosphorylation on Ser and
Thr residues by phospho-amino acid analysis. In vivo vided by John McLauchlan. Plasmids expressing full-
length VP22 (UL49ep) (18), VP22 deleted from residuesphosphate labeling of both transfected and infected COS-
1 cells was carried out as described before, and the 267 to 301 (D267), and VP22 deleted from residues 119
to 301 (D119) (Fig. 2), which all contained a C-terminallabeled extracts were immunoprecipitated, electropho-
resed, and blotted onto PVDF membrane. The 32P-labeled epitope tag, were transfected into COS-1 cells and la-
beled with either [35S]methionine or [32P]orthophosphate.VP22 bands were visualized by autoradiography (Fig. 3a),
excised from the blot, and subjected to acid hydrolysis Soluble extracts were immunoprecipitated with an anti-
body specific for the epitope tag at the 3* end (anti-CMVin 5.7 M HCl for 1 hr at 1107 (15). The resulting hydrolyzed
amino acids were analyzed by 2-D chromatography using late nuclear antigen, Capricorn) and analyzed by SDS–
PAGE. The 35S-labeled profiles (Fig. 3d, 35S samples)unlabeled phospho-serine, phospho-threonine, and pho-
spho-tyrosine as markers. The results of this analysis demonstrate that the overall level of expression of D119
was somewhat reduced in comparison to full-length and(Fig. 3b) demonstrate that VP22 from both transfected
and infected cells is phosphorylated solely on serine D267 variants. However, the relative levels of the 32P-
labeled proteins were the same as the 35S-labeled pro-residues.
To determine the region of VP22 which is phosphory- teins (Fig. 3d, 32P samples), as judged by quantitation
with a PhosphorImager, implying that all three proteinslated in the cell, the same in vivo labeled VP22 was
analyzed by protease cleavage. The 32P-labeled, immu- are equally phosphorylated. Therefore, and in agreement
with the phospho-peptide mapping, the D119 variant ofnoprecipitated VP22 was blotted onto nitrocellulose, the
VP22 band was excised and cleaved overnight in the VP22 is as efficiently phosphorylated in the cell as full-
length VP22, implying that the N-terminal 120 residuespresence of urea at 377 with 0.5 mg of endo-lysine C
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FIG. 3. VP22 phosphorylation in vivo is located on serine residues present in the N-terminal 120 residues of the protein. (a) Immunoprecipitation
of VP22 from in vivo 32P-labeled transfected and infected cell extracts was carried out as for Fig. 2b and analyzed by SDS–PAGE on a 10%
polyacrylamide gel followed by transfer to PVDF membrane. The radiolabeled bands were visualized by autoradiography. T, transfected; I, infected.
(b) The bands from (a) were excised, subjected to acid hydrolysis, and analyzed by 2-dimensional chromatography. The relative migration of cold
markers is shown at the top. S, serine; T, threonine; Y, tyrosine. (c) In vivo 32P-labeled samples were cleaved with the protease endolysine-C,
digested to completion, and analyzed by high-resolution SDS–PAGE. T, transfected; I, infected. (d) COS-1 cells transfected with plasmids UL49ep
(WT), n267, or n119, were labeled in vivo with either [35S]methionine or [32P]orthophosphate. The cell extracts were immunoprecipitated with the
monoclonal antibody specific for the epitope tag and analyzed by SDS–PAGE on a 12% polyacrylamide gel.
of VP22 contain all the phosphorylation sites utilized in sites, only one of which is a serine residue, and four
consensus CKII sites, all of which are serines (Fig. 2).vivo. In addition, the D119 variant of VP22 migrates with
a much slower mobility (22K) than predicted by its Mr To determine if the N-terminus of VP22 can act as a
substrate for either or both of these kinases, in vitro(14K) confirming the result obtained for the migration of
the 13K endo-lysine cleaved peptide. phosphorylation assays of immunoprecipitated VP22
were carried out. Extracts were made from cells trans-Within the 13K peptide of VP22, which we have shown
to be phosphorylated, there are four consensus PKC fected with either full-length (UL49ep) or D119 VP22
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FIG. 4. Casein kinase II phosphorylates VP22 at the N-terminus. (a) COS-1 cell extracts of either UL49ep (WT) or n119 transfections were
immunoprecipitated with the anti-epitope tag antibody and phosphorylated in vitro with either PKC or CKII. The samples were then analyzed by SDS–
PAGE on a 12% polyacrylamide gel. (b) HSV-1 virions, which had been stripped of their envelopes by detergent treatment, were phosphorylated in
vitro in the absence (0) or in the presence (/) of CKII. The resulting phosphoproteins were separated by SDS–PAGE on a 10% polyacrylamide gel.
Short (2 min) and long (15 min) exposures are shown. (c) Phospho-amino acid analysis of in vitro CKII phosphorylated virion VP22 was carried out as
described for Fig. 3b. S, serine. (d) Endolysine-C cleavage of in vitro CKII phosphorylated virion VP22 was carried out as described for Fig. 2c.
plasmids, and immunoprecipitation was carried out with kinase treatment either in the absence or in the presence
of CKII, solubilized, and analyzed by SDS–PAGE. Virionsthe anti-epitope antibody. The washed samples, still
bound to the Protein A– Sepharose beads, were split in are known to have an associated kinase activity present
in the tegument (UL13) (19, 20), such that in vitro phosphory-two and resuspended in either CKII buffer (20 mM Tris
(pH 7.5), 50 mM KCl, and 10 mM MgCl2) or PKC buffer lation carried out in the absence of an added kinase results
in a number of phosphorylated proteins (Fig. 4b, long expo-(20 mM Tris (pH 7.5), 10 mM MgCl2 , 0.5 mM CaCl2 , 100
mg/ml phosphotidylserine, and 20 mg/ml diacylglycerol). sure, lane 0). However, phosphorylation carried out in the
presence of CKII was much more efficient than autophos-Then 10 mCi of gATP was added to each reaction along
with either 166 units of CKII (New England Biolabs) or phorylation (Fig. 4b, short exposure, lane /). Interestingly,
only two proteins within the capsid–tegument structures0.08 units of PKC (Boehringer-Mannheim). The reactions
were left at 307 for 30 min and the samples run on a acted as efficient substrates of CKII in this context—a
protein of 38K, which is likely to be VP22 (see below), and10% polyacrylamide gel. The results show that full-length
VP22 can act as a substrate for both CKII and PKC in a protein of 80K whose identity has not yet been deter-
mined, but which is the correct size for another tegumentthis in vitro assay (Fig. 4a, WT samples). However, while
CKII phosphorylated theD119 variant of VP22 to a similar protein, the product of UL47. The lower phosphorylated
band was confirmed as VP22 by Western blotting (data notlevel as WT (taking into account the lower level of D119
expression), PKC phosphorylation of the N-terminus was shown). To compare CKII phosphorylated VP22 to in vivo
phosphorylated VP22 the phospho-protein was character-greatly reduced in comparison to full-length (Fig. 4a,
D119 samples). These results suggest that in vitro CKII, ized as described before by both phospho-amino acid anal-
ysis and phospho-peptide mapping. The results of theseand not PKC, mimics the phosphorylation observed for
VP22 in vivo (see also below), and therefore it is the likely assays showed that, as for in vivo labeled VP22, all CKII
phosphorylation was present on serine residues (Fig. 4c),candidate for the cellular kinase responsible for VP22
phosphorylation. and all the phosphorylated sites were present in the N-
terminal peptide migrating at 20K (Fig. 4d). Thus the charac-To determine if VP22 present within the virion can act
as a substrate for CKII, intact virions were stripped of their teristics of VP22 phosphorylated in vitro by CKII are identical
to those of VP22 phosphorylated in vivo, strongly implicatingenvelopes by incubation for 1 hr in 10 mM Tris (pH 7.5), 1
mM MgCl2 , 1 mM DTT, and 0.05% NP-40 at 47. The resulting CKII as the major kinase of VP22 within the cell.
In this paper we have shown that the HSV-1 tegumentcapsid–tegument structures were then subjected to in vitro
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protein VP22 is phosphorylated in the cell by the cellular two proteins are located on the outside of the tegument.
Moreover, as it is likely that the capsid–tegument struc-kinase CKII. Phosphorylation of VP22 causes a shift in its
ture is the one presented to the cytosol of the cell uponmobility such that two forms of the protein can be discerned
virus entry, these in vitro phosphorylation events mayby Western blotting, with the phosphorylated form (221) mi-
mimic the situation in the cell. Early phosphorylation ofgrating more slowly than the nonphosphorylated form (222).
VP22 by CKII may provide a mechanism for dissociatingMoreover, 222 accumulates in the cell only when it is syn-
it from the tegument structure, either separately or inthesized during infection where it appears to be specifically
association with VP16, enabling it to reach the correctincorporated into assembling virus particles and does not
subcellular location. Further studies will be required toaccumulate during transient expression. This suggests that
determine the role of phosphorylation in VP22 functionsome aspect of infected cell metabolism, possibly a specific
and dissociation from the tegument.feature, either inhibits phosphorylation or induces dephos-
phorylation of a population of VP22 molecules late in infec-
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